EBMT 2024 | Comparing CAR-T products for aggressive B-cell lymphoma: axi-cel versus tisa-cel
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses a survey comparing the use of CAR-T products axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) across 67 European centers for aggressive B-cell lymphoma. Axi-cel emerged as the favored product due to lower lymphocyte apheresis workload, manufacturing availability, and effectiveness. However, tisa-cel was preferred for older patients due to lower toxicity. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Participation in accredited CME/CPD: IACH, Medscape Oncology, WEBMD
Consultant/strategic advisor: Therakos, Gilead, Novatis, Bristol Myers Squibb, Sanofi, AstraZeneca, MSD, Jazz Pharmaceuticals
Patents/shares or stocks related or unrelated to this presentation: None
Non-financial interests: SAB MaaTPharma
